In dementia and related neurodegenerative disorders, the clinical challenge extends beyond diagnosis to longitudinal monitoring, prognosis, and individualized care planning. Disease trajectories vary substantially among individuals, even within the same diagnostic category, and progression reflects the interaction of biological, cognitive, behavioral, and environmental factors. This heterogeneity makes dementia a particularly compelling candidate for digital twin-inspired approaches that model individual trajectories over time rather than rely on static group averages [14].

Recent work increasingly frames dementia-oriented digital twins as longitudinal, patient-specific models that integrate multimodal data to estimate disease state, predict progression, and support clinical decision-making. These models commonly combine neuroimaging, cognitive testing, clinical assessments, and, more recently, digital and wearable data streams capturing real-world function and behavior [15]. In this context, the most clinically relevant “twin-like” utility lies in trajectory-aware decision support: anticipating care needs, tailoring follow-up intensity, detecting deviations from expected progression, and monitoring response to interventions [16].

At the same time, reviews emphasize that many dementia “digital twins” remain at an early developmental stage: uncertainty quantification, missingness, cross-site generalizability, and prospective decision-grade validation are recurring gaps [17]. Ethical challenges are also prominent, given the vulnerability, complexity of consent, and privacy concerns in passive sensing. A realistic near-term pathway is therefore the development of twin-inspired, longitudinal decision-support tools, validated prospectively and embedded in care, rather than full simulation-capable twins deployed at scale [18, 19].

Multiple sclerosis (MS) is a high-yield addition because it is inherently longitudinal, imaging-rich, and heterogeneous in course and treatment response. Digital twin-style approaches have been proposed to estimate individual-level trajectories and disease-related brain changes from MRI-based models, positioning MS as a pragmatic domain for “twin-inspired” progression forecasting and monitoring [20, 21]. These approaches also show a broader point relevant to neurology: the most credible early digital twins may be those anchored in robust, repeatable measurement modalities (e.g., MRI) with well-defined clinical decision points [22]. Their practical usefulness at present lies less in serving as full clinical twins and more in supporting individualized monitoring and progression forecasting in measurement-rich settings.

A 2025 study describes a “Virtual Parkinsonian patient” that simulates levodopa effects using patient-specific electrophysiological data (including EEG and deep recordings), illustrating mechanistically anchored personalization [23]. This line of work is promising because Parkinson’s management often requires iterative parameter tuning (medication regimens and/or stimulation settings). Mechanistic, updateable models could therefore evolve toward twin-like decision support, provided they demonstrate prospective clinical utility, robustness across recording modalities and sites, and safe integration into workflows where model outputs inform real therapeutic adjustments [24]. At present, these systems are best viewed as promising mechanistic personalization tools rather than established routine-care instruments.

Drug-resistant focal epilepsy remains one of the most precise near-term neurological targets because the clinical question is specific and actionable: estimating the epileptogenic zone network to guide intervention. A 2024 paper presents a high-resolution “virtual brain twin” workflow designed to estimate the epileptogenic zone network using stimulation paradigms, positioning the approach as a personalized, generative, adaptive model intended for scientific and clinical use [12]. This is important because it moves beyond retrospective classification toward patient-specific modeling capable of “what-if” reasoning, exactly the kind of decision-linked value implied by stricter digital twin definitions. Among current neurological applications, this is one of the clearest examples of potential clinical usefulness because the modeled question is specific, actionable, and linked to intervention planning. Even here, one must look for evidence of prospective validation, verification/validation of the model-to-patient mapping, and clarity about how uncertainty is communicated when outputs may affect irreversible decisions [6].

Stroke spans acute decisions and long-term rehabilitation, but the most feasible early “twin-like” value may arise in rehabilitation, where patients generate repeated functional data over time and care is continuously adjusted. A scoping review mapped digital twin objectives, input data, methods, and stakeholder involvement, and proposed “desirable properties”, emphasizing that most current efforts remain early-stage and not yet decision-grade twins under strict criteria [25]. This literature supports a realistic translational pathway: rather than aiming immediately for “full brain twins”, stroke may benefit first from narrow, task-focused twins that monitor recovery and personalize therapy intensity, targets, and timing, where the bidirectional “twin” loop can be operationalized as data to model, to therapy adjustment, to outcome, and to model update [26]. In this sense, the near-term usefulness of stroke twins may be greatest in rehabilitation optimization rather than in attempting comprehensive whole-brain digital replication.

Pain is a major neurological-care burden and offers a useful systems-level framing. A 2025 article proposes “Digital Twin Learning Health Systems”, integrating multimodal biomarkers and adaptive learning loops to personalize pain care, explicitly linking twins to continuous updating and outcome-driven improvement [27]. This perspective is valuable because it connects the digital twin concept to care infrastructure and governance: the twin is not a standalone algorithm, but part of a monitored cycle of data capture, prediction, clinical action, outcome evaluation, and model updating. It also naturally foregrounds issues such as measurement validity, drift, fairness, safety monitoring, and accountability, because the model is explicitly embedded in clinical decision loops [28].

Migraine is characterized by fluctuating symptoms and context sensitivity, making it a logical candidate for twin-like models, provided the measurement layer is strong. The medical hypothesis “Intelligent Digital Twins for Personalized Migraine Care” provides a clear rationale for how migraine twins could be constructed around longitudinal, multidimensional patient data streams and decision-support needs [29]. A 2025 perspective on digital phenotyping argues that continuous, real-world measurement could shift the care toward proactive strategies [30]. At the same time, broader reviews of AI in headache medicine describe emerging interest in wearable-based monitoring and personalized simulation while implying that the evidence base remains preliminary for routine clinical adoption [31]. In this domain, the most likely expectation is to emphasize that “twin-like” progress is currently best framed around validated digital biomarkers, prospective care pathways, and transparent uncertainty, rather than overpromised simulation [32, 33, 34]. Accordingly, their near-term usefulness is likely to depend on whether digital phenotyping can yield reliable and clinically interpretable biomarkers that genuinely improve monitoring or treatment timing in practice.

The first gap concerns clarity and precision in terminology. It should be explicitly stated whether a proposed system represents a static patient-specific model, a periodically updated monitoring tool, a mechanistic simulator, a trial-oriented or prognostic “twin”, or a decision-grade clinical digital twin that meets core criteria such as dynamic updating, predictive capability, uncertainty representation, and decision-linked value.

Aligning terminology with actual system capabilities is essential and shapes expectations for validation, regulatory oversight, clinical trust, and ethical accountability.

A second significant gap concerns the validity and robustness of measurement, particularly in ambulatory and real-world neurological settings. Many proposed digital twins depend on wearable sensors, smartphones, or patient-reported data streams. Without well-validated digital biomarkers that perform reliably across devices, contexts, and populations, model updating risks amplifying noise rather than improving inference. Migraine digital phenotyping illustrates both the opportunity and the challenge of this paradigm. Continuous data streams may enable earlier detection of change and more adaptive care, but only when signals are clinically interpretable, reproducible, and meaningfully linked to outcomes [29, 35]. Similar measurement challenges apply across movement disorders, rehabilitation, and chronic neurological disease, where variability and context sensitivity remain significant obstacles to robust modeling.

A third gap concerns the explicit handling of uncertainty. Neurological digital twins must not only generate predictions but also communicate confidence, limitations, and failure modes. In high-stakes neurological decisions, a clinically useful twin is one that supports reasoning under uncertainty rather than obscuring it. Verification, validation, and uncertainty quantification are increasingly recognized as foundational scientific requirements for digital twins in precision medicine [36]. This includes evaluating model behavior across populations, over time, and under distributional shift. Without these safeguards, even technically advanced systems risk overconfidence, misinterpretation, and unsafe deployment.

The fourth gap lies in evaluation design and real-world deployment. Future studies must move beyond retrospective performance metrics to assess whether digital twins improve clinically meaningful outcomes, such as time to appropriate treatment, functional recovery, quality of life, adverse event rates, or healthcare utilization. Experience from trial-analytics twins in Alzheimer’s disease [37] illustrates that “value” may emerge through multiple pathways, including improved evidence generation, patient stratification, and trial efficiency, not solely through bedside decision support. Evaluation frameworks must therefore be matched to the intended function of each twin type and embedded within realistic clinical workflows.

Finally, governance represents a central and unresolved challenge. Neurological digital twins may integrate highly sensitive longitudinal data and influence high-stakes clinical decisions. Robust frameworks are needed for data stewardship, transparency, auditing, and accountability. Equally important is demonstrating performance across diverse populations to avoid reinforcing existing inequities in neurological care. Governance mechanisms must evolve alongside technical development rather than being treated as an afterthought.

Cost and implementation feasibility must also be considered explicitly. Routine clinical use of neurological digital twins may require substantial investment in multimodal data acquisition, computational infrastructure, interoperability, technical support, and clinician training. These demands may be manageable in highly resourced academic centers but remain challenging for many routine care settings. From a global health perspective, there is a real risk that digital twin technologies could deepen existing inequities in neurological care if they are developed primarily around high-resource infrastructures, proprietary systems, or narrowly represented populations. A realistic translational pathway therefore requires not only technical sophistication, but also scalable, equitable, and context-sensitive implementation models.